CCL2 and glioblastoma: In conclusion, our results support CCL2 to be a potential prognostic factor for GBM and also a predictive biomarker for immunotherapy, providing a rationale for assisting individualized survival prediction and more precise selection of GBM patients who could benefit from immunotherapy.